P.4.c.003 Predictors of clinical outcome in panic disorder: a pooled analysis of venlafaxine extended release short-term treatment studies

2006 ◽  
Vol 16 ◽  
pp. S465-S466
Author(s):  
M. Pollack ◽  
D.J. Stein ◽  
R. Mangano ◽  
R. Entsuah ◽  
N. Simon
Keyword(s):  
Panic Disorder ◽  
Clinical Outcome ◽  
Extended Release ◽  
Pooled Analysis ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment

Predictors of clinical outcome in panic disorder: Analysis of venlafaxine XR short-term treatment studies

2007 ◽  
Vol 22 ◽  
pp. S240
Author(s):  
M. Pollack ◽  
D.J. Stein ◽  
R. Mangano ◽  
J. Musgnung ◽  
R. Entsuah ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Clinical Outcome ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment

scholarly journals Diurnal panic attacks with and without nocturnal panic attacks: are there some phenomenological differences?

2005 ◽  
Vol 27 (3) ◽  
pp. 216-221 ◽  
Author(s):  
Fabiana L Lopes ◽  
Antonio E Nardi ◽  
Isabella Nascimento ◽  
Alexandre M Valença ◽  
Marco A Mezzasalma ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Attention Deficit Disorder ◽  
Panic Attack ◽  
Age At Onset ◽  
Term Treatment ◽  
Panic Attacks ◽  
Short Term ◽  
Short Term Treatment ◽  
Term Outcome ◽  
Cross Sectional

OBJECTIVE: To compare nocturnal and diurnal panic attacks in a cross-sectional study and in a longitudinal prospective short-term follow-up. METHODS: We selected 57 panic disorder (PD) subjects (DSM-IV) and rated them with the Panic Disorder Severity Scale (PDSS) at baseline and after 30 days of treatment with nortriptyline, and with the Eysenck Personality Inventory and the Brown Attention Deficit Disorder (ADD) Scale at baseline. RESULTS: The sample was divided into a nocturnal and diurnal panic attack (NDPA) group - 57.9% (n = 33) - and a diurnal panic attack (DPA) group - 42.1% (n = 24). The groups showed a similar mean age at onset of PD and a pattern of prominent respiratory symptoms. The PDSS did not differ between the groups following short-term treatment (p = 0.451). There were also neither significant differences in Neuroticism (p = 0.094) and Extroversion (p = 0.269) nor in the Brown ADD Scale (p = 0.527). CONCLUSION: In our study, patients with both nocturnal and diurnal panic attacks showed similar features in their phenomenology and short-term outcome when compared to pure diurnal panic attacks patients.

Predictors of short-term treatment response in 66 patients with panic disorder

1994 ◽  
Vol 30 (4) ◽  
pp. 233-241 ◽  
Author(s):  
Donald W. Black ◽  
Robert B. Wesner ◽  
Janelle Gabel ◽  
Wayne Bowers ◽  
Patrick Monahan
Keyword(s):  
Panic Disorder ◽  
Treatment Response ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment

scholarly journals Venlafaxine extended-release capsules in panic disorder

2005 ◽  
Vol 187 (4) ◽  
pp. 352-359 ◽  
Author(s):  
Jacques Bradwejn ◽  
Antti Ahokas ◽  
Dan J. Stein ◽  
Eliseo Salinas ◽  
Gerard Emilien ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Panic Disorder ◽  
Extended Release ◽  
Term Treatment ◽  
Panic Attacks ◽  
Double Blind Study ◽  
Short Term Treatment ◽  
Double Blind ◽  
Proven Efficacy ◽  
To Receive

BackgroundVenlafaxine extended-release (ER) has proven efficacy in the treatment of anxiety symptoms in major depression, generalised anxiety disorder and social anxiety disorder.AimsTo evaluate the efficacy, safety and tolerability of venlafaxine ER in treating panic disorder.MethodAdult out-patients (n=361) with panic disorder were randomly assigned to receive venlafaxine ER (75–225 mg/day) or placebo for up to 10 weeks in a double-blind study.ResultsVenlafaxine ER was not associated with a greater proportion of patients free from full-symptom panic attacks at the finalon-therapy evaluation, but was associated with lower mean panic attack frequency and a higher proportion free from limited-symptom panic attacks, higher response and remission rates, and improvements in anticipatory anxiety, fear and avoidance. Adverse events were comparable with those of the drug in depression and anxiety disorders.ConclusionsVenlafaxine ER seems to be effective and well tolerated in the short-term treatment of panic disorder.

Sign in / Sign up

Export Citation Format

Share Document